Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-05
DOI
10.3389/fimmu.2020.00613
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria
- (2019) Raffi Topakian et al. JOURNAL OF NEUROLOGY
- Rituximab in myasthenia gravis: a “to be or not to be” inhibitor of T cell function
- (2018) Mariapaola Marino et al. Annals of the New York Academy of Sciences
- IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders
- (2018) Maartje G. Huijbers et al. Annals of the New York Academy of Sciences
- Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis
- (2018) Panos Stathopoulos et al. Annals of the New York Academy of Sciences
- On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease
- (2018) David C. Trampert et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Rituximab in refractory myasthenia gravis: extended prospective study results
- (2018) Grayson Beecher et al. MUSCLE & NERVE
- Targeting B Cells and Plasma Cells in Autoimmune Diseases
- (2018) Katharina Hofmann et al. Frontiers in Immunology
- The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis
- (2018) Elena Cortés-Vicente et al. Annals of Clinical and Translational Neurology
- IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients
- (2017) Inga Koneczny et al. JOURNAL OF AUTOIMMUNITY
- Rituximab treatment of myasthenia gravis: A systematic review
- (2017) Rup Tandan et al. MUSCLE & NERVE
- B cells in the pathophysiology of myasthenia gravis
- (2017) John S. Yi et al. MUSCLE & NERVE
- Rituximab as treatment for anti-MuSK myasthenia gravis
- (2017) Michael K. Hehir et al. NEUROLOGY
- Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis
- (2017) Kimberly R. Robeson et al. JAMA Neurology
- Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients
- (2017) Mikael Ebbo et al. PLoS One
- International consensus guidance for management of myasthenia gravis
- (2016) Donald B. Sanders et al. NEUROLOGY
- Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up
- (2016) Dustin Anderson et al. Annals of Clinical and Translational Neurology
- The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
- (2014) Helena Marco et al. BMC MUSCULOSKELETAL DISORDERS
- Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
- (2014) Raffaele Iorio et al. JOURNAL OF NEUROLOGY
- What Is and What Should Always Have Been: Long-Lived Plasma Cells Induced by T Cell-Independent Antigens
- (2013) A. Bortnick et al. JOURNAL OF IMMUNOLOGY
- Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients: Table 1
- (2013) Benison Keung et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
- (2013) M. G. Huijbers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Management challenges in muscle-specific tyrosine kinase myasthenia gravis
- (2012) Amelia Evoli et al. Annals of the New York Academy of Sciences
- Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice
- (2012) Rinse Klooster et al. BRAIN
- Long-lasting treatment effect of rituximab in MuSK myasthenia
- (2012) J. Diaz-Manera et al. NEUROLOGY
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
- (2011) M. H. Buch et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab for the Treatment of IgG4-Related Disease
- (2011) Arezou Khosroshahi et al. MEDICINE
- Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
- (2011) Richard J. Nowak et al. Therapeutic Advances in Neurological Disorders
- Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease
- (2010) Arezou Khosroshahi et al. ARTHRITIS AND RHEUMATISM
- Immunosuppressive therapies in myasthenia gravis
- (2010) Donald B. Sanders et al. AUTOIMMUNITY
- Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece
- (2009) P. Tsiamalos et al. EUROPEAN JOURNAL OF NEUROLOGY
- Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis
- (2008) Daniel B. Drachman et al. Annals of the New York Academy of Sciences
- Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1
- (2008) E.H. Niks et al. JOURNAL OF NEUROIMMUNOLOGY
- B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders
- (2008) J STUBGEN JOURNAL OF NEUROIMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now